Our group suspects that some patients secrete insulin with adequate biological activity based on affected organogenesis pathways and pancreatic insulin synthesis, and that their hepatic insulin sensitivity is sufficient to avoid metabolic disorders. This evidence concerns the gene INS and Other metabolic disease.